Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)
TipRanks (Tue, 14-Jul 12:30 PM ET)
Globe Newswire (Wed, 8-Jul 7:35 AM ET)
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 14-May 8:00 AM ET)
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol CMMB.
As of July 17, 2026, CMMB stock price climbed to $1.56 with 89,417 million shares trading.
CMMB has a beta of 1.35, meaning it tends to be more sensitive to market movements. CMMB has a correlation of 0.05 to the broad based SPY ETF.
CMMB has a market cap of $11.43 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CMMB traded as high as $10.20 and as low as $1.35.
CMMB has underperformed the market in the last year with a price return of -65.5% while the SPY ETF gained +19.5%. CMMB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.6% and -31.3%, respectively, while the SPY returned +4.9% and -0.2%, respectively.
CMMB support price is $1.40 and resistance is $1.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMMB shares will trade within this expected range on the day.